Literature DB >> 23280328

Construction of an inducible cell-communication system that amplifies Salmonella gene expression in tumor tissue.

Yumei Dai1, Bhushan J Toley, Charles A Swofford, Neil S Forbes.   

Abstract

Bacterial therapies have the potential to overcome resistances that cause chemotherapies to fail. When using bacteria to produce anticancer agents in tumors, triggering gene expression is necessary to prevent systemic toxicity. The use of chemical triggers, however, is hampered by poor delivery of inducing molecules, which reduces the number of activated bacteria. To solve this problem, we created a cell-communication system that enables activated bacteria to induce inactive neighbors. We hypothesized that introducing cell communication into Salmonella would improve direct triggering strategies by increasing protein production, increasing sensitivity to inducer molecules, and enabling expression in tumor tissue. To test these hypotheses we integrated the PBAD promoter into the quorum-sensing machinery from Vibrio fischeri. The expression of a fluorescent reporter gene was compared to expression from non-communicating controls. Function in three-dimensional tissue was tested in a tumor-on-a-chip device. Bacterial communication increased fluorescence 40-fold and increased sensitivity to inducer molecules more than 10,000-fold. The system enabled bacteria to activate neighbors and increased the time-scale of protein production. Gene expression was controllable and tightly regulated. At the optimal inducing signal, communicating bacteria produced 350 times more protein than non-communicating bacteria. The cell-communication system created in this study has uses beyond cancer therapy, including protein manufacturing, bioremediation and biosensing. It would enable amplified induction of gene expression in any environment that limits availability of inducer molecules. Ultimately, because inducible cellular communication enables gene expression in tissue, it will be a critical component of bacterial anticancer therapies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23280328     DOI: 10.1002/bit.24816

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  12 in total

1.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

Review 2.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

Review 3.  Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.

Authors:  Gang Xin; David M Schauder; Ryan Zander; Weiguo Cui
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

4.  Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker.

Authors:  Jan T Panteli; Brittany A Forkus; Nele Van Dessel; Neil S Forbes
Journal:  Integr Biol (Camb)       Date:  2015-04       Impact factor: 2.192

Review 5.  Salmonella-Mediated Cancer Therapy: Roles and Potential.

Authors:  Vu Hong Nguyen; Jung-Joon Min
Journal:  Nucl Med Mol Imaging       Date:  2016-06-01

Review 6.  Intratumor microbiome in cancer progression: current developments, challenges and future trends.

Authors:  Jinyan Liu; Yi Zhang
Journal:  Biomark Res       Date:  2022-05-31

7.  Targeted deletion of the ara operon of Salmonella typhimurium enhances L-arabinose accumulation and drives PBAD-promoted expression of anti-cancer toxins and imaging agents.

Authors:  Hyun Hong; Daejin Lim; Geun-Joong Kim; Seung-Hwan Park; Hyeon Sik Kim; Yeongjin Hong; Hyon E Choy; Jung-Joon Min
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 8.  Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy.

Authors:  Christian Ronquillo Pangilinan; Che-Hsin Lee
Journal:  Biomedicines       Date:  2019-05-02

Review 9.  Developing a new class of engineered live bacterial therapeutics to treat human diseases.

Authors:  Mark R Charbonneau; Vincent M Isabella; Ning Li; Caroline B Kurtz
Journal:  Nat Commun       Date:  2020-04-08       Impact factor: 14.919

Review 10.  Bacteria-cancer interactions: bacteria-based cancer therapy.

Authors:  Mai Thi-Quynh Duong; Yeshan Qin; Sung-Hwan You; Jung-Joon Min
Journal:  Exp Mol Med       Date:  2019-12-11       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.